{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-029218","form_type":"8-K","ticker":"RGEN","cik":"0000730272","company_name":"REPLIGEN CORP","filed_at":"2023-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.922200+00:00","generated_at":"2026-06-19T21:08:45.361330+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Repligen appoints Martin D. Madaus to board; board expands to 8","bullets":["Martin Madaus, Ph.D., joined Repligen's board effective Feb 6, 2023, also named to Nominating and Corporate Governance Committee.","Board size increased from seven to eight directors upon Madaus' election.","Madaus received initial option grant valued at $170,000, vesting equally over three years.","Pro-rata equity award of options and RSUs each valued at $21,250, vesting at next annual shareholder meeting.","Madaus brings over 25 years of life sciences tools industry experience, including CEO roles at Millipore and Ortho Clinical Diagnostics."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-029218","json":"https://secwatch.observer/filing/0001193125-23-029218.json","markdown":"https://secwatch.observer/filing/0001193125-23-029218.md","text":"https://secwatch.observer/filing/0001193125-23-029218.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/730272/000119312523029218/0001193125-23-029218-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/730272/000119312523029218/d802605d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T21:08:45.361330+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ce34a1e7cf","claim":"Martin Madaus was elected as Director at REPLIGEN CORP.","evidence_excerpt":"the Board elected Martin Madaus, Ph.D. to the Board, effective February 6, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/730272/000119312523029218/0001193125-23-029218-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}